What's hot

View all perspectives
      New validated BASDAI cut offs. BASDAI values of <2, <4 and >6 are often applied as cut-offs between remission,

      Dr. Antoni Chan synovialjoints

      1 year 3 months ago
      New validated BASDAI cut offs. BASDAI values of <2, <4 and >6 are often applied as cut-offs between remission, low (LDA), high (HDA) and very high (VHDA) disease activity, respectively, although this remains unvalidated. The optimal BASDAI values against external criteria were… https://t.co/5cvWoddHaN https://t.co/oBwYmFsIga
      #EULAR2024 POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characte

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characterisation. Multicentre study in Korea showed protective effect on Serious Infection btw those treated vs not. Effect was seen in the first 3mths only @RheumNow https://t.co/dCzD21589S
      #EULAR2024

      Powerful quote to end @Dr_SBattista’s HPR highlights:

      "People working together in a strong community with

      Mrinalini Dey DrMiniDey

      1 year 3 months ago
      #EULAR2024 Powerful quote to end @Dr_SBattista’s HPR highlights: "People working together in a strong community with a shared goal and a common purpose can make the impossible possible"- Tom Vilsack @RheumNow
      Interdisciplinary collaboration is the key!
      @rheumnow #EULAR2024 https://t.co/pARPUH2ntr

      Bella Mehta bella_mehta

      1 year 3 months ago
      Interdisciplinary collaboration is the key! @rheumnow #EULAR2024 https://t.co/pARPUH2ntr
      Photos of hands/finger folds for RA disease activity - nice idea, challenges++, but with poor photo quality you’re alw

      David Liew drdavidliew

      1 year 3 months ago
      Photos of hands/finger folds for RA disease activity - nice idea, challenges++, but with poor photo quality you’re always struggling. Telehealth has taught us: - ideal settings can work, but - suboptimal inputs inevitably lead to suboptimal results #EULAR2024 POS0451 @RheumNow https://t.co/fyCQzSl6tB
      placebo effects can be huge!
      #EULAR2024 @RheumNow https://t.co/RmcBAPG2Ye

      Bella Mehta bella_mehta

      1 year 3 months ago
      placebo effects can be huge! #EULAR2024 @RheumNow https://t.co/RmcBAPG2Ye
      Fantastic speakers, chairs and faculty for the #PARE session on self-management.

      #EULAR2024 @RheumNow https://t.co/9ulR

      Mrinalini Dey DrMiniDey

      1 year 3 months ago
      Fantastic speakers, chairs and faculty for the #PARE session on self-management. #EULAR2024 @RheumNow https://t.co/9ulRWL2Mnp
      #EULAR2024 highlights

      @Dr_SBattista discusses the beneficial effects of exercise for inflammation and general well-bein

      Mrinalini Dey DrMiniDey

      1 year 3 months ago
      #EULAR2024 highlights @Dr_SBattista discusses the beneficial effects of exercise for inflammation and general well-being, presented by Prof Kitas @RheumNow https://t.co/WAHg4ub8R3
      Have RA and want to get pregnant? What can you do?
      The answer is simple: disease control.

      Implementing T2T in RA led to

      David Liew drdavidliew

      1 year 3 months ago
      Have RA and want to get pregnant? What can you do? The answer is simple: disease control. Implementing T2T in RA led to much better fertility. RA therapy is your friend! #EULAR2024 POS0436 Rotterdam @RheumNow https://t.co/aoxNakMix1
      OP0007 (2024)
      S/C ABA VS ADA H2H COMPARISON ADULTS EARLY, DUAL SEROPOSITIVE RA, +ive FOR SHARED EPITOPE HLA CLASS II RIS

      Peter Nash drpnash

      1 year 3 months ago
      OP0007 (2024) S/C ABA VS ADA H2H COMPARISON ADULTS EARLY, DUAL SEROPOSITIVE RA, +ive FOR SHARED EPITOPE HLA CLASS II RISK ALLELES, & INADEQUATE RESPONSE TO MTX: RESULTS FROM PH3 AMPLIFIED TRIAL shame seropositivity did not translate to an advantage for AbA @RheumNow #EULAR2024
      PARE summary at #EULAR2024 - love the word cloud highlighting the posters @RheumNow
      RA, SLE and JIA were the key RMDs t

      Bella Mehta bella_mehta

      1 year 3 months ago
      PARE summary at #EULAR2024 - love the word cloud highlighting the posters @RheumNow RA, SLE and JIA were the key RMDs that were focused on. By Silvia Aguleria https://t.co/WbSKwE6vXs
      #EULAR2024 POS0375 Negative trial need to be reported too. Phase 2 RCT of S95011, an IL7-R antibody in moderate to sever

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 POS0375 Negative trial need to be reported too. Phase 2 RCT of S95011, an IL7-R antibody in moderate to severe systemic #Sjogren failed to meet primary endpoint (ESSDAI) or other secondary (ESSPRI, biomarkers). This inhibition unlikely to impact on SjD @RheumNow
      EULAR PARE highlights
      - Need close collaboration between patients and physicians.
      -Child to adult transition need to b

      Bella Mehta bella_mehta

      1 year 3 months ago
      EULAR PARE highlights - Need close collaboration between patients and physicians. -Child to adult transition need to be smooth to be successful (30% patients can be lost in transitions) - We need patients to participate in Health Technology Assessment @rheumnow #EULAR2024 https://t.co/50qFpRGXo2
      Another proof (if needed) that controlling DA in RA is a very important preventive measure in RA!

      179 pts
      ILD newly de

      Aurelie Najm AurelieRheumo

      1 year 3 months ago
      Another proof (if needed) that controlling DA in RA is a very important preventive measure in RA! 179 pts ILD newly developed 9.5% progressed 12.3% no change 74.9% improved 4.5% 5.7% in the LDA group 28.0% non-LDA group (p=0.006) @RheumNow #EULAR2024 POS0408 https://t.co/7DyXr5zdCM
      POS0061 (2024)
      INTERCEPTION OF THE DEVELOPMENT OF RA BY 1-YEAR MTX IN ACPA-NEGATIVE ARTHRALGIA PATIENTS AT INCREASED RIS

      Peter Nash drpnash

      1 year 3 months ago
      POS0061 (2024) INTERCEPTION OF THE DEVELOPMENT OF RA BY 1-YEAR MTX IN ACPA-NEGATIVE ARTHRALGIA PATIENTS AT INCREASED RISK FOR RA: 4 YEAR RESULTS OF THE TREAT EARLIER TRIAL MTX reduced development of RA in high risk acpa neg pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

      Podcasts

      • EULAR 2024 SLE Topic Panel
      • EULAR 2024 Psoriatic Arthritis Topic Panel
      • EULAR 2024 Rheumatology Roundup

      Catch up on Conference Podcasts

      ×